

**Te Tāhū Hauora**  
Health Quality & Safety  
Commission

# Infections in aged residential care

Sue Atkins

Infection prevention and control specialist

November 2023



Today we are talking about:

- definitions of infection for residential aged care
- the importance of infection recognition and appropriate treatment
- identification of incontinence-associated dermatitis with or without infection.



# Definitions of infection for aged care


Gastrointestinal	Respiratory	Skin/soft tissue/mucosal	Systemic	Urinary	Constitutional criteria
<p><b>Gastroenteritis</b> Must have at least <u>one</u> criteria:</p> <ol style="list-style-type: none"> <li>Diarrhoea</li> <li>Vomiting</li> <li><u>Both</u> sub-criteria:               <ol style="list-style-type: none"> <li>a stool specimen positive for a pathogen (eg, <i>E. coli</i>)</li> <li>at least <u>one</u> sub-criteria: nausea, vomiting, abdominal pain or tenderness +/- diarrhoea.</li> </ol> </li> </ol> <p><b>Norovirus</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>diarrhoea +/- vomiting</li> <li>stool specimen for which norovirus is detected.</li> </ol> <p><b>Clostridium difficile</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>diarrhoea +/- presence of toxic mega-colon</li> <li>at least <u>one</u> sub-criteria:               <ol style="list-style-type: none"> <li>a positive stool sample for <i>C. difficile</i> toxin A or B, or a toxin-producing <i>C. difficile</i> organism is identified from a stool sample culture or by a molecular diagnostic test such as PCR</li> <li>pseudomembranous colitis is identified during endoscopic examination or surgery or in histo-pathologic examination of a biopsy specimen.</li> </ol> </li> </ol> <p><b>Diarrhoea</b> Three or more liquid or watery stools above what is normal for the resident within a 24-h period.</p> <p><b>Vomiting</b> Two or more episodes of vomiting in a 24-h period.</p>	<p><b>Common cold/pharyngitis</b> Must have at least <u>two</u> criteria:</p> <ol style="list-style-type: none"> <li>runny nose or sneezing</li> <li>stuffy nose</li> <li>sore throat/hoarseness/dysphagia</li> <li>dry cough</li> <li>swollen or tender glands – neck.</li> </ol> <p><b>Influenza</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>fever</li> <li>at least three sub-criteria:               <ol style="list-style-type: none"> <li>chills</li> <li>new headache or eye pain</li> <li>myalgia</li> <li>malaise or loss of appetite</li> <li>sore throat</li> <li>new or increased dry cough.</li> </ol> </li> </ol> <p><b>Pneumonia</b> Must have all criteria:</p> <ol style="list-style-type: none"> <li>recent CXR showing pneumonia or new infiltrate</li> <li>at least <u>one</u> resp sub-criteria</li> <li>at least <u>one</u> constitutional criteria.</li> </ol> <p><b>Lower resp tract infection</b> Must have <u>all</u> criteria:</p> <ol style="list-style-type: none"> <li>no recent CXR</li> <li>at least <u>two</u> resp sub-criteria</li> <li>at least <u>one</u> constitutional criteria.</li> </ol> <p><b>Resp criteria</b></p> <ol style="list-style-type: none"> <li>Increased cough</li> <li>Increased sputum production</li> <li>O<sub>2</sub> saturation &lt;94% on room air or a reduction of &gt;3% from baseline</li> <li>New or changed lung examination abnormalities</li> <li>Pleuritic chest pain</li> <li>Resp rate ≥25 breaths/min.</li> </ol>	<p><b>Cellulitis/soft tissue wound infection</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>pus at wound, skin or soft tissue site</li> <li>four or more sub-criteria:               <ol style="list-style-type: none"> <li>heat</li> <li>redness</li> <li>swelling</li> <li>tenderness or pain</li> <li>serious discharge</li> <li>one constitutional criteria.</li> </ol> </li> </ol> <p><b>Scabies</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>maculo-papular rash</li> <li>at least <u>one</u> sub-criteria:               <ol style="list-style-type: none"> <li>Dr or lab confirmation</li> <li>epidemiologic linkage to lab-confirmed scabies.</li> </ol> </li> </ol> <p><b>Oral candidiasis</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>presence of raised white patches on inflamed mucosa or plaques on oral mucosa</li> <li>Dr or dental provider confirmation.</li> </ol> <p><b>Fungal skin infection</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>characteristic rash or lesions</li> <li>Dr or lab confirmation.</li> </ol> <p><b>Herpes simplex or zoster</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>vesicular rash</li> <li>Dr or lab confirmation.</li> </ol> <p><b>Conjunctivitis</b> Must have <u>one</u> criteria:</p> <ol style="list-style-type: none"> <li>pus appearing from one or both eyes, present for &gt;24 h</li> <li>new or increased conjunctival redness ± itching or pain for &gt;24 h.</li> </ol>	<p><b>Primary bloodstream infection</b> Must have <u>one</u> criteria:</p> <ol style="list-style-type: none"> <li>two or more positive blood cultures (same organism)</li> <li>a single blood culture and at least one of the following:               <ol style="list-style-type: none"> <li>fever</li> <li>hypothermia (&lt;34.5 °C or does not register)</li> <li>drop in SBP of &gt;30 mmHg from baseline</li> <li>worsening mental or functional status.</li> </ol> </li> </ol> <p><b>Unexplained febrile episode</b> Must have documented record of fever on two or more occasions at least 12 h apart in any 3-day period with no known infectious or non-infectious cause.</p>	<p><b>UTI – without IDC</b> Must have at least one criteria:</p> <ol style="list-style-type: none"> <li>acute dysuria or acute pain, swelling or tenderness of the testes, epididymis or prostate</li> <li>fever or leukocytosis and one localised urinary tract sub-criteria.</li> </ol> <p><b>UTI – with IDC</b> Must have at least <u>one</u> criteria:</p> <ol style="list-style-type: none"> <li>fever, rigors or new-onset hypotension, with no alternate site of infection</li> <li>either acute change in mental status or acute functional decline with no alternate diagnosis and leukocytosis</li> <li>new-onset supra-pubic pain or costo-vertebral angle pain or tenderness</li> <li>purulent discharge from around the catheter or acute pain, swelling or tenderness of the testes, epididymis or prostate.</li> </ol> <p><b>Localised urinary tract criteria</b></p> <ol style="list-style-type: none"> <li>IF fever or leukocytosis present, acute costo-vertebral angle pain or tenderness</li> <li>Supra-pubic pain</li> <li>Gross haematuria</li> <li>New or marked increase in incontinence</li> <li>New or marked increase in urgency</li> <li>New or marked increase in frequency</li> </ol>	<p><b>Fever</b></p> <ol style="list-style-type: none"> <li>Single oral temperature &gt;37.8 °C</li> <li>Repeated oral temperatures &gt;37.2 °C or rectal temperatures &gt;37.5 °C</li> </ol> <p>OR</p> <ol style="list-style-type: none"> <li>Single temperature &gt;1.1 °C over baseline from <u>any</u> site (oral, tympanic, axillary)</li> </ol> <p><b>Leukocytosis</b> As according to FBE results:</p> <ol style="list-style-type: none"> <li>neutrophilia (&gt;14,000 leukocytes/mm<sup>3</sup>)</li> </ol> <p>OR</p> <ol style="list-style-type: none"> <li>Left shift (&gt;6% bands or ≥1,500 bands/mm<sup>3</sup>)</li> </ol> <p><b>Acute change in mental status from baseline</b> Must meet all criteria:</p> <ol style="list-style-type: none"> <li>Acute onset</li> <li>Fluctuating course</li> <li>Inattention</li> <li>Either disorganised thinking or altered level of consciousness</li> </ol> <p><b>Acute functional decline</b></p> <ol style="list-style-type: none"> <li>Increase in daily living activity score</li> <li>Bed mobility</li> <li>Transfer</li> <li>Locomotion within facility</li> <li>Dressing</li> <li>Toilet use</li> <li>Personal hygiene</li> <li>Eating</li> </ol> <p><b>Neutrophils</b> Common type of leukocyte.</p> <p><b>Left shift</b> Increase in number of immature leukocytes in peripheral blood.</p>



The Bristol stool chart is a tool to help staff determine whether a resident has diarrhoea.


## Bristol Stool Form Scale

Type 1



Separate hard lumps, like nuts

Type 2



Sausage-shaped but lumpy

Type 3



Like a sausage but with cracks on its surface

Type 4




Like a sausage or snake, smooth and soft

Type 5



Soft blobs with clear-cut edges

Type 6



Fluffy pieces with ragged edges, a mushy stool

Type 7



Watery, no solid pieces

Constipated stool - Types 1 or 2

Diarrheal stool - Types 6 or 7

Copyright 2000 © Rome Foundation. All Rights Reserved

[theromefoundation.org](http://theromefoundation.org)



## Australian Aged Care National Antimicrobial Prescribing Survey (AC NAPS)

Participating in AC NAPS supports aged care facilities to identify areas for improvement in:

- antimicrobial use
- preventing infections
- helping reduce antimicrobial resistance and
- helps to improve care for residents.

The infection definitions used in the survey are based on the McGeer et al. infection surveillance definitions.



## AC NAPS 2020 results

823 aged care facilities participated:

- 725 aged care homes
- 98 multipurpose services
- 46,922 residents surveyed



## Most common indications for antimicrobial prescriptions


The top 5 known indications for prescribing antimicrobials were:

- other – skin, soft tissue or mucosal
- cystitis
- tinea
- wound infection (non-surgical) and
- cellulitis

About one-third met the McGeer et al. infection surveillance definitions.

Royal Melbourne Hospital and the National Centre for Antimicrobial Stewardship, figure 8.  
Source: Antimicrobial and infection form section 2, method 1 and 2 data. Only top 20 indications for antimicrobial prescriptions listed. Unknown indications for commencing an antimicrobial excluded. COPD = chronic obstructive pulmonary disease; UTI = urinary tract infection.

## Most common indications for antimicrobial prescriptions, aged care NAPS contributors, 2017–2020




## Most commonly prescribed antimicrobials

6,382 antimicrobials were still prescribed on the survey day:

- 76 percent of prescriptions were for therapeutic use and the remainder were for prophylaxis.
- 23.9 percent were for clotrimazole (topical antifungal).

Royal Melbourne Hospital and the National Centre for Antimicrobial Stewardship, figure 5. Only top 20 antimicrobials prescribed listed. Denominator = all 8,322 antimicrobials prescribed. O = oral; PRN = as needed (pro re nata); T = topical. Kenacomb® contains triamcinolone, neomycin, nystatin and gramicidin.









# Definitions of infection for aged care

Gastrointestinal	Respiratory	Skin/soft tissue/mucosal	Systemic	Urinary	Constitutional criteria
<p><b>Gastroenteritis</b> Must have at least <u>one</u> criteria:</p> <ol style="list-style-type: none"> <li>Diarrhoea</li> <li>Vomiting</li> <li><u>Both</u> sub-criteria:               <ol style="list-style-type: none"> <li>a stool specimen positive for a pathogen (eg, <i>E. coli</i>)</li> <li>at least <u>one</u> sub-criteria: nausea, vomiting, abdominal pain or tenderness +/- diarrhoea.</li> </ol> </li> </ol> <p><b>Norovirus</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>diarrhoea +/- vomiting</li> <li>stool specimen for which norovirus is detected.</li> </ol> <p><b>Clostridium difficile</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>diarrhoea +/- presence of toxic mega-colon</li> <li>at least <u>one</u> sub-criteria:               <ol style="list-style-type: none"> <li>a positive stool sample for <i>C. difficile</i> toxin A or B, or a toxin-producing <i>C. difficile</i> organism is identified from a stool sample culture or by a molecular diagnostic test such as PCR</li> <li>pseudomembranous colitis is identified during endoscopic examination or surgery or in histo-pathologic examination of a biopsy specimen.</li> </ol> </li> </ol> <p><b>Diarrhoea</b> Three or more liquid or watery stools above what is normal for the resident within a 24-h period.</p> <p><b>Vomiting</b> Two or more episodes of vomiting in a 24-h period.</p>	<p><b>Common cold/pharyngitis</b> Must have at least <u>two</u> criteria:</p> <ol style="list-style-type: none"> <li>runny nose or sneezing</li> <li>stuffy nose</li> <li>sore throat/hoarseness/dysphagia</li> <li>dry cough</li> <li>swollen or tender glands – neck.</li> </ol> <p><b>Influenza</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>fever</li> <li>at least three sub-criteria:               <ol style="list-style-type: none"> <li>chills</li> <li>new headache or eye pain</li> <li>myalgia</li> <li>malaise or loss of appetite</li> <li>sore throat</li> <li>new or increased dry cough.</li> </ol> </li> </ol> <p><b>Pneumonia</b> Must have <u>all</u> criteria:</p> <ol style="list-style-type: none"> <li>recent CXR showing pneumonia or new infiltrate</li> <li>at least <u>one</u> resp sub-criteria</li> <li>at least <u>one</u> constitutional criteria.</li> </ol> <p><b>Lower resp tract infection</b> Must have <u>all</u> criteria:</p> <ol style="list-style-type: none"> <li>no recent CXR</li> <li>at least <u>two</u> resp sub-criteria</li> <li>at least <u>one</u> constitutional criteria.</li> </ol> <p><b>Resp criteria</b></p> <ol style="list-style-type: none"> <li>Increased cough</li> <li>Increased sputum production</li> <li>O<sub>2</sub> saturation &lt;94% on room air or a reduction of &gt;3% from baseline</li> <li>New or changed lung examination abnormalities</li> <li>Pleuritic chest pain</li> <li>Resp rate ≥25 breaths/min.</li> </ol>	<p><b>Cellulitis/soft tissue wound infection</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>pus at wound, skin or soft tissue site</li> <li>four or more sub-criteria:               <ol style="list-style-type: none"> <li>heat</li> <li>redness</li> <li>swelling</li> <li>tenderness or pain</li> <li>serious discharge</li> <li>one constitutional criteria.</li> </ol> </li> </ol> <p><b>Scabies</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>maculo-papular rash</li> <li>at least <u>one</u> sub-criteria:               <ol style="list-style-type: none"> <li>Dr or lab confirmation</li> <li>epidemiologic linkage to lab-confirmed scabies.</li> </ol> </li> </ol> <p><b>Oral candidiasis</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>presence of raised white patches on inflamed mucosa or plaques on oral mucosa</li> <li>Dr or dental provider confirmation.</li> </ol> <p><b>Fungal skin infection</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>characteristic rash or lesions</li> <li>Dr or lab confirmation.</li> </ol> <p><b>Herpes simplex or zoster</b> Must have <u>both</u> criteria:</p> <ol style="list-style-type: none"> <li>vesicular rash</li> <li>Dr or lab confirmation.</li> </ol> <p><b>Conjunctivitis</b> Must have <u>one</u> criteria:</p> <ol style="list-style-type: none"> <li>pus appearing from one or both eyes, present for &gt;24 h</li> <li>new or increased conjunctival redness ± itching or pain for &gt;24 h.</li> </ol>	<p><b>Primary bloodstream infection</b> Must have <u>one</u> criteria:</p> <ol style="list-style-type: none"> <li>two or more positive blood cultures (same organism)</li> <li>a single blood culture and at least one of the following:               <ol style="list-style-type: none"> <li>fever</li> <li>hypothermia (&lt;34.5 °C or does not register)</li> <li>drop in SBP of &gt;30 mmHg from baseline</li> <li>worsening mental or functional status.</li> </ol> </li> </ol> <p><b>Unexplained febrile episode</b> Must have documented record of fever on two or more occasions at least 12 h apart in any 3-day period with no known infectious or non-infectious cause.</p>	<p><b>UTI – without IDC</b> Must have at least one criteria:</p> <ol style="list-style-type: none"> <li>acute dysuria or acute pain, swelling or tenderness of the testes, epididymis or prostate</li> <li>fever or leukocytosis and one localised urinary tract sub-criteria.</li> </ol> <p><b>UTI – with IDC</b> Must have at least <u>one</u> criteria:</p> <ol style="list-style-type: none"> <li>fever, rigors or new-onset hypotension, with no alternate site of infection</li> <li>either acute change in mental status or acute functional decline with no alternate diagnosis and leukocytosis</li> <li>new-onset supra-pubic pain or costo-vertebral angle pain or tenderness</li> <li>purulent discharge from around the catheter or acute pain, swelling or tenderness of the testes, epididymis or prostate.</li> </ol> <p><b>Localised urinary tract criteria</b></p> <ol style="list-style-type: none"> <li>IF fever or leukocytosis present, acute costo-vertebral angle pain or tenderness</li> <li>Supra-pubic pain</li> <li>Gross haematuria</li> <li>New or marked increase in incontinence</li> <li>New or marked increase in urgency</li> <li>New or marked increase in frequency</li> </ol>	<p><b>Fever</b></p> <ol style="list-style-type: none"> <li>Single oral temperature &gt;37.8 °C</li> <li>Repeated oral temperatures &gt;37.2 °C or rectal temperatures &gt;37.5 °C</li> </ol> <p>OR</p> <ol style="list-style-type: none"> <li>Single temperature &gt;1.1 °C over baseline from <u>any</u> site (oral, tympanic, axillary)</li> </ol> <p><b>Leukocytosis</b> As according to FBE results:</p> <ol style="list-style-type: none"> <li>neutrophilia (&gt;14,000 leukocytes/mm<sup>3</sup>)</li> </ol> <p>OR</p> <ol style="list-style-type: none"> <li>Left shift (&gt;6% bands or ≥1,500 bands/mm<sup>3</sup>)</li> </ol> <p><b>Acute change in mental status from baseline</b> Must meet all criteria:</p> <ol style="list-style-type: none"> <li>Acute onset</li> <li>Fluctuating course</li> <li>Inattention</li> <li>Either disorganised thinking or altered level of consciousness</li> </ol> <p><b>Acute functional decline</b></p> <ol style="list-style-type: none"> <li>Increase in daily living activity score</li> <li>Bed mobility</li> <li>Transfer</li> <li>Locomotion within facility</li> <li>Dressing</li> <li>Toilet use</li> <li>Personal hygiene</li> <li>Eating</li> </ol> <p><b>Neutrophils</b> Common type of leukocyte.</p> <p><b>Left shift</b> Increase in number of immature leukocytes in peripheral blood.</p>

## Incontinence Associated Dermatitis with Suspected Infection

Incorporating the Ghent Global IAD Categorisation Tool (GLOBIAD) <sup>1</sup> and Antimicrobial Stewardship Recommendations

Incontinence Associated Dermatitis (IAD) is the skin damage associated with exposure to urine or faeces.  
**RISK FACTORS INCLUDE** ■ incontinence ■ use of occlusive containment products ■ compromised mobility ■ damaged skin integrity ■ diminished cognitive awareness ■ inability to perform personal hygiene ■ pain ■ raised body temperature ■ poor nutrition ■ medications (eg: immunosuppressants) ■ critical illness ■ poor hygiene ■ inappropriate application of barrier cream ■ comorbidities (eg: diabetes\*)

ASSESSMENT		MANAGEMENT	
CATEGORY	CRITICAL CRITERIA	ADDITIONAL CRITERIA	TARGETED MEASURES Use in addition to core measures
<b>1A: Persistent redness WITHOUT clinical signs of infection</b> 	<ul style="list-style-type: none"> <li>Persistent redness A variety of tones of redness may be present. In persons with darker skin tones, the skin may be paler or darker than normal, or purple in colour.</li> </ul>	<ul style="list-style-type: none"> <li>Marked areas or discolouration from a previous (healed) skin defect</li> <li>Shiny appearance of the skin</li> <li>Macerated skin</li> <li>Intact vesicles or bullae</li> <li>Skin may feel tense or swollen at palpation</li> <li>Burning, tingling, itching or pain</li> </ul>	<p><b>CORE MEASURES</b> Use for all IAD categories</p> <ul style="list-style-type: none"> <li>Investigate for and manage the preventable causes of incontinence such as urinary tract infection, faecal impaction, excessive urine output, delirium etc.<sup>2</sup></li> <li>Screen for pressure injury risk and manage accordingly.<sup>3</sup></li> </ul> <p><b>MONITOR, CLEANSE, PROTECT, RESTORE and MONITOR</b> again.</p> <p><b>ALL persons who are incontinent require a skin management regime</b></p> <p><b>TARGETED MEASURES</b> Use in addition to core measures</p> <p><b>Persistent redness WITHOUT clinical signs of infection</b></p> <ul style="list-style-type: none"> <li>Do <b>NOT</b> prescribe antimicrobial agents, including antifungal creams.</li> </ul> <p><b>Persistent redness WITH clinical signs of infection</b></p> <ul style="list-style-type: none"> <li>See medication therapy (page 2): -If suspected fungal infection, apply antifungal cream.</li> <li>-If suspected bacterial infection, administer antibiotics.</li> <li>Apply barrier product after antifungal cream (see page 2).</li> <li>Document the reason, name, dose, route of administration, (if topical, exact site of application), intended duration and review plan for each prescribed medication.</li> <li>Refer to a Continence Advisor or Wound Specialist/Consultant (with dedicated hours for this role) if no improvement after 3-5 days.</li> </ul> <p><b>Skin loss WITHOUT clinical signs of infection</b></p> <ul style="list-style-type: none"> <li>Do <b>not</b> prescribe antimicrobial agents, including antifungal creams.</li> </ul> <p><b>Skin loss WITH clinical signs of infection</b></p> <ul style="list-style-type: none"> <li>See medication therapy (page 2): -If suspected fungal infection, apply antifungal cream.</li> <li>-If suspected bacterial infection, administer antibiotics.</li> <li>Apply barrier product after antifungal cream (see page 2).</li> <li>Document the reason, name, dose, route of administration, (if topical, exact site of application), intended duration and review plan for the prescribed medication(s).</li> <li>Take microbiology samples only for suspected bacterial infections. Clean first before swabbing at exudate site.</li> <li>Refer to a Continence Advisor or Wound Specialist/Consultant (with dedicated hours for this role) if no improvement after 3-5 days.</li> </ul>
<b>1B: Persistent redness WITH clinical signs of infection</b> 	<ul style="list-style-type: none"> <li>Persistent redness: As above.</li> <li>Signs of infection: such as - White scaling of the skin (suggesting a fungal infection)</li> <li>- Satellite pustule lesions (suggesting a Candida albicans fungal infection).</li> </ul>	<ul style="list-style-type: none"> <li>Marked areas or discolouration from a previous (healed) skin defect</li> <li>Shiny appearance of the skin</li> <li>Macerated skin</li> <li>Intact vesicles or bullae</li> <li>Skin may feel tense or swollen at palpation</li> <li>Burning, tingling, itching or pain</li> </ul>	
<b>2A: Skin loss WITHOUT clinical signs of infection</b> 	<ul style="list-style-type: none"> <li>Skin loss May present as skin erosion (may result from damaged/eroded vesicles or bullae), denudation or excoriation. The skin damage pattern may be diffuse.</li> </ul>	<ul style="list-style-type: none"> <li>Persistent redness. A variety of tones of redness may be present. In persons with darker skin tones, the skin may be paler or darker than normal, or purple in colour.</li> <li>Marked areas or discolouration from a previous (healed) skin defect</li> <li>Shiny appearance of the skin</li> <li>Macerated skin</li> <li>Intact vesicles or bullae</li> <li>Skin may feel tense or swollen at palpation</li> <li>Burning, tingling, itching or pain</li> </ul>	
<b>2B: Skin loss WITH clinical signs of infection</b> 	<ul style="list-style-type: none"> <li>Skin loss: As above</li> <li>Signs of infection: such as - White scaling of the skin (suggesting a fungal infection)</li> <li>- Satellite pustule lesions (suggesting a Candida albicans fungal infection).</li> <li>- Slough (yellow/brown/greyish) visible in the wound bed</li> <li>- Green appearance within the wound bed, suggesting a Pseudomonas aeruginosa (bacterial) infection,</li> <li>- Excessive exudate levels,</li> <li>- Purulent exudate (pus), or</li> <li>- Shiny appearance of the wound bed.</li> </ul>	<ul style="list-style-type: none"> <li>Persistent redness. A variety of tones of redness may be present. In persons with darker skin tones, the skin may be paler or darker than normal, or purple in colour.</li> <li>Marked areas or discolouration from a previous (healed) skin defect</li> <li>Shiny appearance of the skin</li> <li>Macerated skin</li> <li>Intact vesicles or bullae</li> <li>Skin may feel tense or swollen at palpation</li> <li>Burning, tingling, itching or pain</li> </ul>	

\* 1. If on an SGLT2 inhibitor, refer to GP for cessation of medication. 2. If BGL > 10 mmol per litre (and not on an SGLT2 inhibitor) refer to a Credentialed Diabetes Educator

**Differential diagnosis**  
 It is important to exclude pressure injuries, dermatologic conditions (eg. psoriasis), other bacterial and viral (e.g. herpes zoster) infections





## 2023 frailty care guides

As Aotearoa New Zealand's aged population increases, the recognition and treatment of frailty has become crucial to all health care environments. It:

- is a recognised clinical syndrome
- requires specialised assessment
- requires specialised interventions.





## 2023 frailty care guides

The frailty care guides:

- focus on the aged residential care environment
- may also be helpful in other health care settings
- are designed for use by health care professionals
- support rather than replace clinical judgement.



## 2023 frailty care guides

- [Urinary incontinence | Te turuturu o te mimi](#)
- [Urinary tract infections | Te pokenga pūaha mimi](#)
- [Wound assessment | Te aromatawai taotū](#)
- [Wound care | Te maimoatanga ō ngā taotū](#)

**Frailty  
care  
guides**

**Ngā  
aratohu  
maimoa  
hauwarea**



## References

- Royal Melbourne Hospital and the National Centre for Antimicrobial Stewardship. 2023. Antimicrobial prescribing practice in Australian residential aged care facilities: results of the 2020 Hospital National Antimicrobial Prescribing Survey. Canberra: Department of Health and Aged Care. URL: [irp.cdn-website.com/d820f98f/files/uploaded/antimicrobial-prescribing-in-australian-residential-aged-care-facilities-results-of-the-2020-aged-care-national-antimicrobial-prescribing-survey.pdf](http://irp.cdn-website.com/d820f98f/files/uploaded/antimicrobial-prescribing-in-australian-residential-aged-care-facilities-results-of-the-2020-aged-care-national-antimicrobial-prescribing-survey.pdf)
- Stone N, et al. 2012. Surveillance definitions of infections in long-term care facilities: revisiting the McGeer criteria. *Infection Control and Hospital Epidemiology* 33(10): 965–77. DOI: 10.1086/667743.





## References

- Te Tāhū Hauora Health Quality & Safety Commission. 2023. Frailty care guides | Ngā aratohu maimoa hauwarea (2023 edition). Wellington: Te Tāhū Hauora. URL: [www.hqsc.govt.nz/resources/resource-library/frailty-care-guides-nga-aratohu-maimoa-hauwarea-2023-edition](http://www.hqsc.govt.nz/resources/resource-library/frailty-care-guides-nga-aratohu-maimoa-hauwarea-2023-edition)
- VICNISS – Health Associated Infection Surveillance Coordinating Centre. Incontinence associated dermatitis with suspected infection. URL: [www.vicniss.org.au/media/2089/iad\\_landscape-october-2019.pdf](http://www.vicniss.org.au/media/2089/iad_landscape-october-2019.pdf)

